Related Experiment Video
Updated: Apr 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Optimal stroke prevention in the geriatric patient with atrial fibrillation: position paper of an interdisciplinary
Insights
Geriatric patients with atrial fibrillation (AF) should generally receive oral anticoagulation for stroke prevention. Comprehensive assessments guide treatment decisions, with novel oral anticoagulants (NOACs) offering improved safety and efficacy in this population.
Area of Science:
- Geriatrics
- Cardiology
- Neurology
Background:
- Optimal stroke prevention in geriatric patients with atrial fibrillation (AF) remains unclear.
- Geriatric AF patients often undertreated due to comorbidities, adherence concerns, and bleeding risks, particularly falls.
- Established risk scores indicate a clear need for anticoagulation in high-risk geriatric AF patients.
Purpose of the Study:
- To provide expert recommendations on stroke prevention in geriatric patients with atrial fibrillation.
- To address challenges in anticoagulation management for elderly patients with AF.
Main Methods:
- Summary of an expert panel discussion among hospital-based and office-based physicians experienced in geriatric care.
- Review of current evidence and clinical practice regarding anticoagulation in elderly AF patients.
Main Results:
- Geriatric patients should receive oral anticoagulation unless a thorough assessment indicates otherwise.
- Patients with a history of falls require comprehensive evaluation; those with CHADS2 score ≥ 2 should be anticoagulated regardless of fall risk.
- Novel oral anticoagulants (NOACs) present an improved benefit-risk ratio over vitamin K antagonists in geriatric AF patients, simplifying management.
Conclusions:
- Oral anticoagulation is recommended as a standard treatment for geriatric patients with AF.
- Individualized assessment, including validated geriatric tools, is crucial for treatment decisions.
- NOACs offer advantages in managing AF-related stroke risk in the elderly, with non-renally eliminated options being preferable.
Background:
The optimal approach to stroke prevention in geriatric patients with atrial fibrillation (AF) has not been adequately clarified. Despite their high risk of stroke and clear indication for anticoagulation according to established risk scores, in practice geriatric AF patients often are withheld treatment because of comorbidities and comedications, concerns about low treatment adherence or fear of bleeding events, in particular due to falls.
Method:
The present position paper summarises the outcomes of an expert panel discussion held by hospital-based and office-based physicians with ample experience in the treatment of geriatric patients.
Results And Conclusions:
The panel agreed that geriatric patients should receive oral anticoagulation as a rule, unless a comprehensive neurological and geriatric assessment (including clinical examination, gait tests and validated instruments such as Modified Rankin Scale, Mini-mental state examination or Timed Test of Money Counting) provides sound reasons for refraining from treatment AII patients with a history of falls should be thoroughly evaluated for further evaluation of the causes. Patients with CHADS2 score ≥ 2 should receive anticoagulation even if at high risk for falls. The novel oral anticoagulants (NOAC) facilitate management in the geriatric population with AF (no INR monitoring needed, easier bridging during interventions) and have an improved benefit-risk ratio compared to vitamin K antagonists. Drugs with predominantly non-renal elimination are safer in geriatric
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Dysrhythmias VI: Management of Dysrhythmias
Atherosclerosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Atherosclerosis III: Management
Drug Dosing: Geriatric Patients

